Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Heparin/lidocaine/sodium bicarbonate - Urigen Pharmaceuticals

Drug Profile

Heparin/lidocaine/sodium bicarbonate - Urigen Pharmaceuticals

Alternative Names: Alkalised lidocaine and heparin formulation - Urigen Pharmaceuticals; Hep-Lido-A compounded formulation; U 101; URG-101

Latest Information Update: 14 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Urigen Pharmaceuticals
  • Class Acetanilides; Alkalinising agents; Heparins; Local anaesthetics; Small molecules; Urologics
  • Mechanism of Action Factor Xa inhibitors; Sodium channel antagonists; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Interstitial cystitis
  • Discontinued Cystitis; Dyspareunia

Most Recent Events

  • 31 Dec 2018 Imprimis Pharmaceuticals changed its name to Harrow Health and added all ophthalmology business to its subsidiary ImprimisRx
  • 18 Jun 2018 Urigen terminates a phase II trial for Interstitial Cystitis in USA, based on interim study analysis (NCT02591199)
  • 18 May 2015 Efficacy and pharmacokinetics data from a clinical trial in Interstitial cystitis released by Imprimis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top